1. Home
  2. GRC vs NTLA Comparison

GRC vs NTLA Comparison

Compare GRC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gorman-Rupp Company (The)

GRC

Gorman-Rupp Company (The)

HOLD

Current Price

$74.89

Market Cap

1.9B

Sector

Industrials

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$14.02

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRC
NTLA
Founded
1933
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.5B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
GRC
NTLA
Price
$74.89
$14.02
Analyst Decision
Buy
Analyst Count
0
23
Target Price
N/A
$20.02
AVG Volume (30 Days)
86.5K
5.7M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
1.04%
N/A
EPS Growth
32.03
27.43
EPS
0.68
N/A
Revenue
$682,389,000.00
$67,671,000.00
Revenue This Year
$6.62
N/A
Revenue Next Year
$4.66
$62.75
P/E Ratio
$110.06
N/A
Revenue Growth
3.44
16.92
52 Week Low
$34.96
$6.92
52 Week High
$79.54
$28.24

Technical Indicators

Market Signals
Indicator
GRC
NTLA
Relative Strength Index (RSI) 55.18 55.33
Support Level $43.10 $11.71
Resistance Level $79.02 $15.53
Average True Range (ATR) 2.25 0.99
MACD -0.28 0.09
Stochastic Oscillator 62.97 59.84

Price Performance

Historical Comparison
GRC
NTLA

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: